Chen Xin-Xin, Zhao Si-Ting, Yang Xian-Miao, He Shan-Chuan, Qian Fen-Hong
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China.
Oncol Lett. 2023 Feb 15;25(4):135. doi: 10.3892/ol.2023.13721. eCollection 2023 Apr.
The present study aimed to evaluate the potential of the monocyte to red blood cell count ratio (MRR), the neutrophil to red blood cell count ratio (NRR), the lymphocyte to red blood cell count ratio (LRR) and the product of lymphocyte count and albumin concentration (LA) for the diagnosis of lung cancer. The cases of 216 patients with newly diagnosed lung cancer and 184 healthy volunteers were retrospectively analysed. The MRR and NRR were found to be higher in patients with lung cancer compared with those in healthy controls, while the LRR and LA were lower. The receiver operating characteristic curve analysis revealed that of the four markers, the MRR and LA yielded a higher area under the curve (AUC) (MRR: AUC, 0.810; 95% CI, 0.768-0.847; and LA: AUC, 0.721; 95% CI, 0.674-0.764). The combination of MRR, LA, carcinoembryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) achieved the highest diagnostic value when compared with other single or combined markers (AUC, 0.882; 95% CI, 0.846-0.912; sensitivity, 81.9%; specificity, 81.0%). As the disease progressed, the MRR tended to increase, while LA exhibited a decreasing trend. Binary logistic regression analysis revealed an increase in the MRR, as well as in CEA and CYFRA21-1 concentrations, and a decrease in the LA, which could all be possible risk factors for lung cancer. Differences in the MRR and LA between patients with early stage (IA-IIIA) lung cancer and healthy controls were observed. Further analysis revealed that the MRR also exhibited the potential to detect early stage (IA-IIIA) lung cancer in the model. The present findings demonstrated that the MRR and LA may be used as auxiliary biomarkers for the diagnosis of lung cancer and could partly indicate disease progression.
本研究旨在评估单核细胞与红细胞计数比值（MRR）、中性粒细胞与红细胞计数比值（NRR）、淋巴细胞与红细胞计数比值（LRR）以及淋巴细胞计数与白蛋白浓度乘积（LA）在肺癌诊断中的潜力。对216例新诊断肺癌患者和184例健康志愿者的病例进行回顾性分析。发现肺癌患者的MRR和NRR高于健康对照组，而LRR和LA则较低。受试者工作特征曲线分析显示，在这四种标志物中，MRR和LA的曲线下面积（AUC）较高（MRR：AUC，0.810；95%可信区间，0.768 - 0.847；LA：AUC，0.721；95%可信区间，0.674 - 0.764）。与其他单一或联合标志物相比，MRR、LA、癌胚抗原（CEA）和细胞角蛋白19片段抗原21 - 1（CYFRA21 - 1）联合使用时诊断价值最高（AUC，0.882；95%可信区间，0.846 - 0.912；敏感性，81.9%；特异性，81.0%）。随着疾病进展，MRR有升高趋势，而LA呈下降趋势。二元逻辑回归分析显示，MRR、CEA和CYFRA21 - 1浓度升高以及LA降低均可能是肺癌的危险因素。观察到早期（IA - IIIA期）肺癌患者与健康对照组之间MRR和LA存在差异。进一步分析表明，在该模型中MRR也具有检测早期（IA - IIIA期）肺癌的潜力。本研究结果表明，MRR和LA可作为肺癌诊断的辅助生物标志物，并能部分指示疾病进展。
